首页> 美国卫生研究院文献>Oncotarget >A childhood chemotherapy protocol improves overall survival among adults with T-lymphoblastic lymphoma
【2h】

A childhood chemotherapy protocol improves overall survival among adults with T-lymphoblastic lymphoma

机译:儿童期化疗方案可改善T型淋巴母细胞淋巴瘤成人的总体生存率

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。

摘要

A broadly accepted standard treatment for adult T-lymphoblastic lymphoma (T-LBL) has not yet been defined. To address that issue, we retrospectively compared three chemotherapy regimens used to treat 110 adult patients with newly diagnosed T-LBL. These included two adult regimens (ECOG2993 and hyper-CVAD) and a childhood regimen (BFM-90). These intensive drug regimens are mainly used to treat childhood and adult acute lymphoblastic leukemia. They included induction, consolidation, and maintenance chemotherapy protocols and were administered over the course of 2 years. Seventy-five patients (80%) achieved a complete remission (CR). Within a median follow-up time of 31 months (range: 5–152 months), the 5-year overall survival (OS) and progression-free survival (PFS) rates were 47.7% (95% CI, 35.0–69.8%) and 45.7% (95% CI, 27.6–56.6%), respectively. Shorter survival was associated with age > 40 years, poor ECOG PS and bone marrow involvement. Elevated lactic dehydrogenase (LDH) level, Ann Arbor stage and International Prognostic Index (IPI) score had no prognostic value. The childhood chemotherapy regimen improved CR and the overall survival rate more than the adult regimen in patients aged < 40 years.
机译:成人T淋巴细胞淋巴瘤(T-LBL)的广泛接受的标准治疗方法尚未确定。为了解决该问题,我们回顾性地比较了三种用于治疗110例新诊断为T-LBL的成年患者的化疗方案。其中包括两个成人方案(ECOG2993和hyper-CVAD)和一个儿童方案(BFM-90)。这些强化药物疗法主要用于治疗儿童和成人急性淋巴细胞白血病。它们包括诱导,巩固和维持化疗方案,并且在2年的时间内进行了给药。七十五名患者(80%)达到了完全缓解(CR)。在31个月的中位随访时间内(5-125个月),5年总生存(OS)和无进展生存(PFS)率为47.7%(95%CI,35.0-69.8%)和45.7%(95%CI,27.6–56.6%)。存活时间短与年龄> 40岁,ECOG PS差和骨髓受累有关。乳酸脱氢酶(LDH)水平升高,Ann Arbor分期和国际预后指数(IPI)评分均无预后价值。对于小于40岁的患者,儿童期化疗方案比成人方案改善了CR和总生存率。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号